イルミナ取締役会

Dr. Gottlieb has been a director since February 2020. Dr. Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration from 2017 to 2019. He was elected Chairman of the Board of Directors in March 2025. His work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. He is currently a Special Partner at the venture capital firm New Enterprise Associates and a Resident Fellow at the American Enterprise Institute for Public Policy Research, and he serves as a director of Pfizer, Aetion, Tempus Labs, National Resilience and the Mount Sinai Medical System. Dr. Gottlieb held several roles in the public and private sectors prior to serving as FDA Commissioner, including serving as a venture partner at New Enterprise Associates from 2007 to 2017. Dr. Gottlieb was previously the FDA's Deputy Commissioner for Medical and Scientific Affairs from 2005 to 2007, as well as a senior advisor to the FDA Commissioner from 2003 to 2004. He was also a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services in 2004. Dr. Gottlieb has advised the states of Massachusetts, Maryland, and Montana on the Covid response as a member of state advisory boards. He is a contributor to CNBC and CBS Face the Nation.

Dr. Gottlieb received a B.A. in economics from Wesleyan University and his M.D. from the Icahn School of Medicine at Mount Sinai.

Jacob Thaysen is Chief Executive Officer of Illumina. Prior to joining the company in 2023, Thaysen served as president of the Life Sciences and Applied Markets Group and Diagnostic and Genomics Group at Agilent; corporate vice president of R&D at Dako; and management consultant at Copenhagen Consultancy Company (now Bain & Co). Early in his career, he was founder and chief technology officer of Cantion, a research and defense application development company based in Denmark. Thaysen is Chairman of the ALDA Board (Analytical, Life Science and Diagnostic Association) and is a San Diego Chapter member of the American Cancer Society’s CEOs Against Cancer. Thaysen holds an MSc and PhD in physics from the Technical University of Denmark.

Ms. Dorsa has been a director since January 2017. Ms. Dorsa served as Executive Vice President and Chief Financial Officer of Public Service Enterprise Group Incorporated, a NYSE-listed diversified energy company, from April 2009 until her retirement in October 2015, and served on its Board of Directors from 2003 to April 2009. From February 2008 to April 2009, she served as Senior Vice President, Global Human Health, Strategy and Integration at Merck & Co., Inc., a NYSE-listed pharmaceutical company. From November 2007 to January 2008, Ms. Dorsa served as Senior Vice President and Chief Financial Officer of Gilead Sciences, Inc., a Nasdaq-listed life sciences company. From February 2007 to November 2007, she served as Senior Vice President and Chief Financial Officer of Avaya, Inc., a NYSE-listed telecommunications company. From 1987 to January 2007, Ms. Dorsa held various financial and operational positions at Merck & Co., Inc., including Vice President and Treasurer, Executive Director of U.S. Customer Marketing, and Executive Director of U.S. Pricing and Strategic Planning.

Ms. Dorsa also serves as the Chair of the Board of Directors of Biogen Inc. and on the Board of Duke Energy. She previously served on the Board of Intellia Therapeutics, Inc. From 2016 to 2021, she also served on the Board of Trustees of the Goldman Sachs ETF Trust, the Goldman Sachs MLP and Energy Renaissance Fund and the Goldman Sachs MLP Income Opportunities Fund, investment funds within the Goldman Sachs fund complex.

Ms. Dorsa received her M.B.A. from Columbia University and a B.A. from Colgate University.

David P. King was elected to Illumina’s Board of Directors in 2026. Mr. King has extensive experience in the healthcare and life sciences sectors in executive and non-executive roles, including leading complex businesses at scale, driving operational excellence and commercial initiatives, and executing transformational change through M&A and organic growth.

Mr. King served as Chair and Chief Executive Officer as well as Executive Chairman of Laboratory Corporation of America Holdings (Labcorp) from 2007 to 2019. He provides strategic advisory services across the healthcare ecosystem through KingMan LLC. Mr. King also serves as Chair of Privia Health Group, Inc., as a director of Smith & Nephew, and has served in board leadership roles across a range of healthcare companies, including as Chair of ZimVie (2022–2025) and as Non-Executive Chair of PathGroup, LGC Limited, and AmSurg. Earlier in his career, Mr. King was a partner at Hogan & Hartson LLP (now Hogan Lovells) and served as an Assistant U.S. Attorney for the District of Maryland.   

Mr. King received a B.A. from Princeton University and a J.D. from the University of Pennsylvania Law School. 

Keith Meister was appointed as a director in March 2025. Mr. Meister is the Managing Partner and Chief Investment Officer of Corvex Management LP, which he founded in December 2010.

Prior to founding Corvex, Mr. Meister served as Chief Executive Officer and then Principal Executive Officer and Vice Chairman of the Board of Icahn Enterprises from August 2003 to August 2010.

In addition to Illumina, Mr. Meister currently serves on the Board of Directors for GeneDx, MGM Resorts and Vestis. He has previously served as a director on numerous other public boards including Yum! Brands, Inc., The Williams Companies, The ADT Corporation, Ralcorp Holdings, and Motorola/Motorola Mobility, among others. He is also Chairman of the Board of Directors for Harlem Children’s Zone and a member of the Board of Trustees for the American Museum of Natural History.

Keith received an A.B. in government, cum laude, from Harvard College in 1995.

Anna Richo retired from Cargill, Inc., where she was the General Counsel, Chief Compliance Officer and Corporate Secretary.  In addition to her global responsibilities for law and compliance, she oversaw Global Government Relations, Global Security and Shareholder Relations, and was a member of Cargill's Executive Team.  With a law career spanning more than 35 years, Anna wore multiple hats and has extensive experience in compliance and business ethics, intellectual property and corporate litigation.

Before joining Cargill, Anna was executive vice president and general counsel at UCB, a biopharmaceutical company based in Belgium, where she resided for many years.  She also served as senior vice president and chief compliance officer at Amgen, a global biotechnology firm, and as chief litigation counsel, associate general counsel and vice president of law at Baxter Healthcare.  Her broad international experience extends throughout Europe, Latin America and Asia and has served to strengthen her commitment to championing diversity, equity and inclusion in the workplace.

A native New Yorker, Anna holds a Bachelor of Science degree in industrial and labor relations from Cornell University and a Juris Doctor degree from the College of Law at DePaul University.  Anna is a member of the Board of Directors of Exelon Corporation (NASDAQ: EXC), the nation’s largest energy delivery company, a member of the Board of Directors of Illumina, Inc. (NASDAQ: ILMN), a global human genomics DNA sequencing company, a member of the Board of Trustees of DePaul University, and is a member of Children’s Minnesota Governance Board.  Anna formerly served on the Board of Directors of Adamas Pharmaceuticals, a publicly traded neurology company, from 2020-2021, subsequently acquired by Supernus Pharmaceuticals, and on the Board of Directors of Cytyc Corporation, a publicly traded medical diagnostics company, from 1998-2003, subsequently acquired by Hologic Inc. Additionally, Anna served on the Board of Directors for the California Manufacturers & Technology Association, a statewide nonprofit association, from 2000-2003, where she was Vice-Chairman of the Board.

Mr. Schiller has been a director since July 2016. Mr. Schiller is currently an Apple Fellow at Apple Inc. He rejoined Apple Inc. in April 1997 and began serving as Senior Vice President, Worldwide Marketing in February 2002 as a member of Apple's executive team responsible for the company's product marketing, developer relations, business marketing, education marketing, international marketing, and App Store programs. He has helped Apple create and market some of the best-selling products in the world including the Mac, iPod, iTunes, iPhone, the App Store, Apple TV, and the Apple Watch. Prior to rejoining Apple, Mr. Schiller was Vice President of Product Marketing at Macromedia, Inc. from 1995 to 1997 and Director of Product Marketing at FirePower Systems, Inc. from 1993 to 1995. Prior to that, Mr. Schiller spent six years at Apple in various marketing positions.

Mr. Schiller received a B.S. in biology from Boston College.

Sue Siegel has been a director since February 2019. She has driven game-changing ideas and powered companies that advance industries and improve lives for more than three decades. With vast experience across industries, she is on the forefront of the Fourth Industrial Revolution and is helping companies identify and seize transformative digital opportunities.

Most recently, as GE's Chief Innovation Officer and CEO of GE Ventures & Licensing, Sue oversaw investments in startups, created and scaled new companies, and commercialized GE's intellectual property. She also led strategy planning and oversaw the global marketing function.

Before joining GE, Sue was a Silicon Valley-based healthcare and life sciences VC, leading investments in precision medicine, digital health, and life science tools. Prior to becoming a venture capitalist, Sue led Affymetrix as President and board member, where she led the company's transformation from a pre-revenue startup to a global, multi-billion-dollar market cap genomics leader. Sue also held executive leadership roles at Amersham, DuPont, and Bio-Rad after transitioning to a corporate career from early academic work in molecular biology and biochemistry.

Sue also serves on the boards of Align Technologies (ALGN), Nevro (NVRO), the Kaiser Family Foundation, and is the Chair of MIT's The Engine. Additionally, she serves on the advisory boards for Mass General Brigham's Innovation Growth Board, University of California Innovation Council, RAND Health Care and the U.K. National Health Services Digital Academy. She co-chairs Stanford Medicine Board of Fellows.

Sue was a founding representative board member of NIH's National Center for Advancing Translational Sciences and served on President Obama's Precision Medicine Initiative Working Group.

A leader in technology and business, Sue has been recognized in Fortune's "34 Leaders Who Are Changing Health Care", as one of "The 100 Most Influential Women in Silicon Valley" by Silicon Valley Business Journal and as one of the “Women Continuing to Change the World” by McKinsey & Company. She is an Aspen Institute Henry Crown Fellow and is a featured "Multiplier" in the bestselling book: "Multipliers: How the Best Leaders Make Everyone Smarter."

Ms. Siegel holds a B.S. in Biology from the University of Puerto Rico and a M.S. in Biochemistry and Molecular Biology from Boston University School of Medicine.

Daniel M. Skovronsky, MD, PhD, was appointed as a director in June 2026. Dr. Skovronsky currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, where he leads Lilly’s global research and development organization and oversees commercial products across Lilly Cardiometabolic Health, Lilly Immunology, and Lilly Neuroscience.

He joined Lilly in 2010 following the acquisition of Avid Radiopharmaceuticals, a company he founded in 2004 and led as Chief Executive Officer. Since joining Lilly, he has held roles of increasing responsibility across the organization and currently oversees Lilly’s External Innovation Team, including Catalyze360, which supports biotech innovation through strategic capital, technology, and research capabilities.

He previously served on the Board of Directors of Myriad Genetics, Inc.

Dr. Skovronsky completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his MD from the Perelman School of Medicine, University of Pennsylvania, in 2001 and his PhD in neuroscience from the University of Pennsylvania in 2000. He earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994.

Scott Ullem was appointed as a director in 2023. Mr. Ullem is the Chief Financial Officer of Edwards Lifesciences (EW), a global leader in patient-focused innovations for structural heart disease and critical care monitoring. He joined Edwards in 2014 and has responsibility for global finance, information technology, risk management, indirect sourcing and investor relations.

Prior to joining Edwards, Mr. Ullem was Chief Financial Officer of Bemis Company (BMS), a materials science company engaged in design and manufacturing of flexible packaging and pressure sensitive materials.

Previously, Scott was an investment banker at Goldman Sachs in New York and Chicago and later at Bank of America. Mr. Ullem worked with public and private companies in multiple industries on mergers and acquisitions as well as debt and equity financing.

Since 2016, Mr. Ullem has served on the board of directors of Berry Global. He also serves on the board of egnite, a digital health technology company headquartered in Aliso Viejo, California. Mr. Ullem is a Henry Crown Fellow at the Aspen Institute and a former adjunct professor of finance at Northwestern University’s Kellogg School of Management. He received his bachelor's degree in political science from DePauw University and his master's degree in business administration from Harvard Business School.